Renal impairment (RI) is a frequent complication of patients with newly diagnosed multiple myeloma (NDMM), reported in 15-40% with 10% requiring hemodialysis (HD). It is associated with higher early mortality (EM) and lower overall survival (OS). Early diagnosis and treatment with new agents improve these results.
Carfilzomib es un inhibidor selectivo del proteosoma recientemente aprobado para el tratamiento del mieloma múltiple recaído/refractario (MMRR) en pacientes que recibieron bortezomib y drogas inmunomoduladoras.
Uruguayan population is 3,4 million, mostly caucasian (88%). Life expectancy is 77 years. Cancer is the second cause of death and the estimated incidence of Multiple Myeloma (MM) is 120 cases/year. Its diagnosis and monitoring are standardized and feasible, available nationwide. Treatment with Bortezomib, Thalidomide and stem cell transplant are available for all patients, regardless of their health care provider. However, there is no accurate data on MM incidence, care, treatment-results or mortality. The Uruguayan National Myeloma Registry is designed to document current clinical characteristics of newly diagnosed MM, management and outcome in a real-world setting. This information will be useful to plan strategies to improve our local approach and follow-up of this disease, reducing problems derived from extrapolating data from other realities.